Clearside Biomedical Future Growth
Future criteria checks 2/6
Clearside Biomedical is forecast to grow earnings and revenue by 45.4% and 61.2% per annum respectively while EPS is expected to grow by 44.6% per annum.
Key information
45.4%
Earnings growth rate
44.6%
EPS growth rate
Pharmaceuticals earnings growth | 23.5% |
Revenue growth rate | 61.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 May 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Clearside Biomedical's early-stage wet AMD study gets underway
Jan 12Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares
Jan 12Clearside Bio drops 11% on launch of $12M direct offering
Jan 06Clearside Biomedical: SCS Microinjector Platform With Significant Upside
Jan 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 26 | -43 | N/A | N/A | 3 |
12/31/2025 | 7 | -42 | N/A | N/A | 4 |
12/31/2024 | 1 | -42 | N/A | N/A | 4 |
3/31/2024 | 8 | -35 | N/A | N/A | N/A |
12/31/2023 | 8 | -32 | -20 | -18 | N/A |
9/30/2023 | 2 | -37 | -26 | -24 | N/A |
6/30/2023 | 2 | -36 | -26 | -24 | N/A |
3/31/2023 | 1 | -35 | -25 | -24 | N/A |
12/31/2022 | 1 | -33 | -14 | -13 | N/A |
9/30/2022 | 27 | -5 | -3 | -3 | N/A |
6/30/2022 | 29 | -2 | 0 | 0 | N/A |
3/31/2022 | 30 | 0 | -1 | -1 | N/A |
12/31/2021 | 30 | 0 | -11 | -11 | N/A |
9/30/2021 | 4 | -25 | -20 | -20 | N/A |
6/30/2021 | 4 | -23 | -20 | -20 | N/A |
3/31/2021 | 4 | -23 | -16 | -16 | N/A |
12/31/2020 | 8 | -18 | -13 | -13 | N/A |
9/30/2020 | 10 | -14 | -7 | -7 | N/A |
6/30/2020 | 7 | -18 | -10 | -10 | N/A |
3/31/2020 | 6 | -18 | -17 | -17 | N/A |
12/31/2019 | 2 | -31 | -27 | -27 | N/A |
9/30/2019 | 0 | -49 | -53 | -53 | N/A |
6/30/2019 | 0 | -67 | -67 | -67 | N/A |
3/31/2019 | 0 | -82 | -76 | -76 | N/A |
12/31/2018 | 0 | -83 | -79 | -79 | N/A |
9/30/2018 | 0 | -78 | -70 | -70 | N/A |
6/30/2018 | 0 | -72 | -64 | -64 | N/A |
3/31/2018 | 0 | -65 | -56 | -56 | N/A |
12/31/2017 | 0 | -59 | N/A | -51 | N/A |
9/30/2017 | 0 | -52 | N/A | -42 | N/A |
6/30/2017 | 0 | -39 | N/A | -35 | N/A |
3/31/2017 | 0 | -31 | N/A | -29 | N/A |
12/31/2016 | 1 | -26 | N/A | -23 | N/A |
9/30/2016 | 1 | -21 | N/A | -20 | N/A |
6/30/2016 | 1 | -19 | N/A | -17 | N/A |
3/31/2016 | 1 | -19 | N/A | -15 | N/A |
12/31/2015 | N/A | -18 | N/A | -14 | N/A |
9/30/2015 | N/A | -15 | N/A | -13 | N/A |
6/30/2015 | N/A | -15 | N/A | -13 | N/A |
3/31/2015 | N/A | -12 | N/A | -11 | N/A |
12/31/2014 | N/A | -10 | N/A | -9 | N/A |
9/30/2014 | N/A | -9 | N/A | -8 | N/A |
6/30/2014 | N/A | -8 | N/A | -7 | N/A |
3/31/2014 | N/A | -8 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLSD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLSD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLSD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLSD's revenue (61.2% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: CLSD's revenue (61.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLSD's Return on Equity is forecast to be high in 3 years time